Description du projet
L’automatisation des tests de résistance des agents pathogènes aux antibiotiques
La résistance des agents pathogènes aux antibiotiques représente une menace globale croissante qui entraîne des millions de décès chaque année. L’une des principales raisons du nombre croissant d’agents pathogènes résistants est l’utilisation non optimale des antibiotiques. L’application ciblée d’antibiotiques à spectre étroit est préférable, mais les tests manuels actuels de résistance sont laborieux, alors que les tests automatiques disponibles évaluent un nombre limité d’antibiotiques. Le projet BacterOMIC, financé par l’UE, développe un système de test de susceptibilité antimicrobienne entièrement automatisé pour identifier rapidement (moins de quatre heures) les antibiotiques efficaces parmi tous ceux qui sont habituellement disponibles pour traiter certains agents pathogènes. Il est important de noter que le nouveau système permet l’identification d’une combinaison de plusieurs antibiotiques pour obtenir le traitement le plus efficace. Le projet implique une collaboration internationale au sein de l’UE, et l’objectif actuel de phase 2 consiste à optimiser le concept instrumental et à valider le système dans des essais cliniques avant une future commercialisation.
Objectif
In the recent years, we have seen a drastic increase in the antibiotic resistance among bacterial pathogens. This is considered as one of the biggest threats to global health in the current era. The reason for that is inappropriate use of antibiotics - patients are often treated with not optimal antibiotic that need to be changed after few days. Number of resistant microorganisms constantly elevates due to inappropriate use of antibiotics - patients are often treated with inappropriate drugs that need to be changed after few days if bacteria turns to be resistant. The reason for that is that current manual antibiotic resistance tests are time-consuming and laborious, while automatic antimicrobial tests offer analysis of a short lists of antibiotics.
BacterOMIC is a response to the growing global threat of antibiotic resistance. We provide the first fully comprehensive rapid Antimicrobial Susceptibility Testing (AST) system to determine already in 4h which from all common antibiotics will be most successful in treating certain bacterial infection. Unlike current methods, our system also allows to investigate antimicrobial effect of not only single antibiotics but also combinations of multiple antibiotics – the future of infection disease treatment.
Constantly growing antimicrobial susceptibility testing market was valued at EUR 2.4 billion in 2018 and is expected to reach EUR 3.1 billion by 2022 at the CAGR of 5.1%. With our clear business model we target pharmaceutical and biotechnology companies, contract research organizations, hospitals/private healthcare centers, and diagnostic laboratories. We have a network of partnerships across the EU (PL, FR, ES, CH, DE, and PT) and we are ready for rapid scale-up, with more than 30 million cumulative profit by 2025. We need SME Instrument phase 2 to optimize the design, prepare for mass production, validate the system in clinical trials, and certify it for successful commercialization.
Champ scientifique
- natural sciencesbiological sciencesmicrobiologybacteriology
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Mots‑clés
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
01 796 Warsaw
Pologne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.